Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
The U.S. Supreme Court has granted certiorari in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. to resolve whether generic drug makers’ marketing statements can support inducement claims of patent infringement when using skinny labels that omit patented uses. The case tests the boundaries of Hatch-Waxman’s Sect…
Share This Article
Ready-to-post copy includes the article link.
Supreme Court to Address Induced Infringement Claims in Generic ‘Skinny Label’ Drug Marketing Dispute The U.S. Supreme Court has granted certiorari in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. to resolve whether generic drug makers’ marketing statements can support inducement claims of patent infringement wh... Read the full IIPLA article: https://iipla.org/news/supreme-court-to-address-induced-infringement-claims-in-generic-skinny-label-drug-marketing-dispute